Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCLA UCSD
Dates
study started
estimated completion

Description

Summary

The study objective is to determine the biomarker status of a participant's tumor tissue and use that status to determine eligibility for a linked Roche clinical trial.

Official Title

Master Screening Study to Determine Biomarker Status and Potential Trial Eligibility for Patients With Malignant Tumors

Keywords

Solid Tumors Neoplasms Screening platform

Eligibility

For people ages 18 years and up

General Inclusion Criteria:

  • Confirmed availability of a representative formalin-fixed, paraffin-embedded (FFPE) tumor specimen meeting criteria defined in the protocol
  • Considered by principal investigator (PI) to be a candidate for a linked clinical trial with an investigational medicinal product, and that the participant has the awareness and willingness to participate in said trial

Inclusion Criteria for Participants with Stage III NSCLC

  • Locally advanced, unresectable Stage III NSCLC of either squamous or non-squamous histology based on 8th edition of the American Joint Committee on Cancer (AJCC) and Union for International Cancer Control (UICC) cancer staging system
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

General Exclusion Criteria:

  • History of malignancy other than NSCLC within 5 years prior to screening, except for malignancies with a negligible risk of metastasis or death
  • Any condition that may affect the interpretation of study results
  • Significant liver or cardiovascular disease
  • Prior allogenic stem-cell or solid-organ transplantation

Locations

  • UCLA Department of Medicine; Division of Hematology / Oncology
    California City California 90095 United States
  • Moores Cancer Center at UC San Diego Health
    La Jolla California 92093 United States
  • Southern California Kaiser Permanente
    San Diego California 92108 United States

Details

Status
not yet accepting patients
Start Date
Completion Date
(estimated)
Sponsor
Hoffmann-La Roche
ID
NCT05419375
Phase
Phase 2 Solid Tumor Research Study
Study Type
Interventional
Participants
Expecting 15000 study participants
Last Updated